Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Clinical trial NCT02342613 · COMPLETED
Trial details
- NCT number
- NCT02342613
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-28
- Primary completion
- 2023-11-29
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.